Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm41Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbas...
Guardado en:
Autores principales: | Ansari J, Hussain SA, Ansari A, Glaholm J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b5690e7855164f9cb41a6a6e28736910 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Eva Juengel, et al.
Publicado: (2021) -
Tivozanib in the treatment of renal cell carcinoma
por: Hepgur M, et al.
Publicado: (2013) -
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Yuki Katsumata, et al.
Publicado: (2021) -
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Ori Toker, et al.
Publicado: (2010) -
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Peter E Clark
Publicado: (2010)